Want to understand why some antibodies succeed as therapeutic agents? Do you want to know which targets are on the increase and which receive the most approvals?
Want to know which antibodies are in clinical trials and how they're doing?
Dr Janice Reichert, Assistant Professor Research at Tufts Center for the Study of Drug Development and Editor-in-Chief of mAbs, covered all of these questions and more at the 2011 European Antibody Congress;
Antibody therapeutics development – state of the art
- Industry benchmarks for antibody-based therapeutics development
- Effects of new Ab and alternative formats in the pipeline
- New results for probabilities of success
Do you want to find out more?